Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC

Phase 1

Completed

• Conditions: Neoplasms; Lung Cancer
• Interventions: Biological: Anti-PD-1 alone; Biological: Anti-PD-1 plus DC-CIK

• Registration Number: NCT03360630
• Lead Sponsor: Capital Medical University

Brief Summary

A randomized controlled study to compared the clinical effects and safety of immunotherapy with dendritic cells and cytokine-induced killer cells administered with anti-PD-1 antibody in advanced NSCLC.

Detailed Description

Not available

Study Timeline

• Study Start: 2016-11-01
• Study First Submitted: 2017-11-27
• Study First Submitted QC: 2017-12-01
• Study First Posted: 2017-12-04
• Primary Completion: 2022-12-31
• Study Completion: 2023-06-01
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-05
• Last Update Posted: 2024-02-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Histologically or cytologically confirmed advanced or metastatic NSCLC.
• Patients must have received previously standard therapy for that malignancy or declined to chemotherapy/radiotherapy.
• Estimated life expectancy > 3 months.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2.
• Age 18 to 80.
• Adequate hematologic function, with WBC ≥ 3000/microliter, hemoglobin ≥ 9 g/dL (it is acceptable to have had prior transfusion), platelets ≥ 75,000/microliter; PT-INR <1.5 (unless patient is receiving warfarin in which case PT-INR must be <3), PTT <1.5X ULN
• Adequate renal and hepatic function, with serum creatinine < 1.5 mg/ dL, bilirubin < 1.5 mg/dL (except for Gilbert's syndrome which will allow bilirubin ≤ 2.0 mg/dL), ALT and AST ≤ 2.5 x upper limit of normal.

Exclusion Criteria

• Patients with a history of autoimmune disease, such as but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis. Autoimmune related thyroid disease and vitiligo are permitted.
• Patients with serious intercurrent chronic or acute illness, such as cardiac disease (NYHA class III or IV), hepatic disease, or other illness considered by the Principal Investigator as unwarranted high risk for investigational drug treatment.
• Patients with a medical or psychological impediment to probable compliance with the protocol should be excluded.
• Concurrent (or within the last 5 years) second malignancy other than non melanoma skin cancer, cervical carcinoma in situ, controlled superficial bladder cancer, or other carcinoma in situ that has been treated.
• Presence of an active acute or chronic infection including: a urinary tract infection, HIV (as determined by ELISA and confirmed by Western Blot). Patients with HIV are excluded based on immuno-suppression, which may render them unable to respond to the vaccine; patients with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections.
• Patients on chronic steroid therapy (or other immuno-suppressives, such as azathioprine or cyclosporin A) are excluded on the basis of potential immune suppression. Patients must have had 6 weeks of discontinuation of any steroid therapy (except that used as pre-medication for chemotherapy or contrast-enhanced studies or for acute treatment (<5 days) of intercurrent medical condition such as a gout flare) prior to enrollment.
• Pregnant and nursing women should be excluded from the protocol since this research may have unknown and harmful effects on an unborn child or on young children. If the patient is sexually active, the patient must agree to use a medically acceptable form of birth control while receiving treatment and for a period of 4 months following the last vaccination therapy. It is not known whether the treatment used in this study could affect the sperm and could potentially harm a child that may be fathered while on this study.
• Patients with acute or chronic skin disorders that will interfere with injection into the skin of the extremities or subsequent assessment of potential skin reactions will be excluded.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Anti-PD-1 alone	Anti-PD-1 alone	-
Anti-PD-1 plus DC-CIK	Anti-PD-1 plus DC-CIK	-

Primary Outcome Measures

Name	Time	Method
Progression-free survival of the participants	12 months	From starting date of anti-PD-1 antibody treatment until date of until the date of first documented disease progression or date of death from any cause, whichever comes first.

Secondary Outcome Measures

Name	Time	Method
Assessment of Patient- Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PROCTCAE)	24 months	To assess and compare the PRO-CTCAE by patients receiving immunotherapy
Overall survival of the participants(OS)	24 months	From starting date of anti-PD-1 antibody treatment until date of death from any cause
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	24 months
Molecular Tumor Burden Index	24 months	Using mutation detection in ctDNA by liquid biopsy to assess tumor dynamics

Trial Locations

Locations (1)

Capital Medical Unvierstiy Cancer Center/ Beijing Shijitan Hospital; 🇨🇳 Beijing, China